Breaking News Headlines Today | Ground News

See every side of every news story

ophthalmologytimes.com image

News from ophthalmologytimes.com

We’ve assigned a media bias rating of unknown to ophthalmologytimes.com. You can read more about our methodology here.

ophthalmologytimes.com’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about ophthalmologytimes.com

Where is ophthalmologytimes.com located?ophthalmologytimes.com's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top ophthalmologytimes.com News

Sagent Announces Launch of Travoprost Ophthalmic Solution, USP

Borger · Borger

Sagent Announces Launch of Travoprost Ophthalmic Solution, USP

100% Center coverage: 8 sources

/PRNewswire/ -- Sagent Pharmaceuticals ("Sagent"), a leading provider of pharmaceuticals to the US market, today announced its entry into the ophthalmic market...See the Story

Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates

Waltham, Massachusetts · Waltham

Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates

100% Center coverage: 1 sources

WALTHAM, Mass.--(BUSINESS WIRE)--Sep 15, 2025-See the Story

$180M+ Sales Milestone Deal: Ocugen Partners with Korean Pharma Giant for Breakthrough Eye Gene Therapy

Innovation · South Korea

$180M+ Sales Milestone Deal: Ocugen Partners with Korean Pharma Giant for Breakthrough Eye Gene Therapy

Ocugen licenses OCU400 gene therapy for retinitis pigmentosa to Kwangdong Pharma, including $7.5M upfront, $180M+ in milestones, and 25% royalties. Phase 3 BLA filing targeted for 2026.See the Story

Breaking News Topics Related to ophthalmologytimes.com